Mallinckrodt plc (NYSE: MNK), a global specialty pharmaceutical and medical imaging business, today reported results for the fourth quarter of fiscal 2013, which ended September 27, 2013.
Net sales were $552.2 million for the fourth quarter of fiscal 2013, an increase of 7.6%, compared with $513.1 million reported in the fourth quarter of fiscal 2012. Operational growth was 8.2% as movements in foreign exchange rates negatively impacted net sales.
Help employers find you! Check out all the jobs and post your resume.
